Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Micvotabart-pelidotin (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms KEYNOTE-G17
  • Sponsors Pyxis Oncology

Most Recent Events

  • 13 Oct 2025 According to Pyxis Oncology media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (October 17-21, 2025)
  • 18 Mar 2025 According to Pyxis Oncology media release, the company aims to select a dose of micvotabart pelidotin in combination with pembrolizumab by mid-year 2025.
  • 03 Mar 2025 Planned initiation date changed from 15 Feb 2025 to 31 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top